Strand Life Sciences Launches Olink Explore HT Proteomics Platform for Biomarker Discovery

Strand Life Sciences has expanded its analytical capabilities with the addition of the Olink Explore HT proteomics platform, a development that carries direct implications for biopharma teams managing biomarker qualification and protein characterization within drug development pipelines.

The platform enables simultaneous analysis of thousands of proteins from a single sample, a throughput profile that compresses timelines typically associated with large-scale proteomics studies. For development-stage programs where biomarker discovery runs parallel to early process validation, the ability to interrogate the proteome at this resolution without multiplying sample volumes represents a meaningful operational shift.

For QA directors and analytical development leads, the relevance sharpens around characterization workflows. Protein-based therapeutics and complex biologics require extensive quality characterization data to satisfy ICH Q6B expectations and support regulatory submissions. Platforms capable of high-multiplex protein quantification reduce the number of discrete assays required, which in turn tightens data packages and shortens the analytical development cycle.

Strand Life Sciences, headquartered in Bengaluru, positions the capability within its broader contract research and diagnostics infrastructure. The addition of Olink Explore HT extends the company's offering to Indian biopharma sponsors seeking high-resolution proteomic data without establishing in-house instrumentation, a consideration that carries weight for mid-sized developers operating under constrained capital expenditure.

The platform's proximity to clinical and translational research programs also has regulatory consequence. Biomarker data generated during development must meet fit-for-purpose validation standards before supporting labeling claims or companion diagnostic submissions; the analytical rigor of the underlying platform is therefore a submission-readiness variable, not merely a discovery convenience.

Adoption of Olink Explore HT across the Indian biopharma CRO landscape will be measured against how sponsors integrate high-multiplex proteomic data into existing regulatory dossiers and biomarker qualification frameworks.

Source: Media4Growth via Indian Pharma Post, 18 May 2026.